DiamiR Biosciences Secures EU Patent Covering the Use of microRNA Biomarkers from Bodily Fluids for Differential Diagnosis of Amyotrophic Lateral Sclerosis
2024年8月1日 - 9:02PM
DiamiR, a developer of innovative blood-based diagnostic tests for
brain health and other diseases, today announced that the Company’s
European Patent Application No. 17 771018.3 titled: “Methods
of using miRNAs from bodily fluids for detection and
differentiation of neurodegenerative diseases” was granted by the
European Patent Office under number 3 433 381. The
patent, which is set to expire in March 2037, claims the use of
methods developed by DiamiR for early diagnosis of amyotrophic
lateral sclerosis (ALS).
The corresponding US patent application No.
16/086,881 was granted by the United States Patent & Trademark
Office (USPTO) on October 19, 2021 as US 4,149,313 with claims to
detecting and monitoring neurodegenerative disorders in association
with treatment.
DiamiR now has 52 issued patents in the US and
worldwide comprising seven families of patents and covering early
detection, differential diagnosis, and monitoring of disease and
aging with microRNA signatures detectable in bodily fluids,
including blood plasma.
"Allowance of this new patent by the European
Patent Office further strengthens DiamiR's global IP portfolio
focused on early detection, prediction of progression and
monitoring of brain health and other conditions," said
Dr. Samuil Umansky, Chief Scientific Officer of DiamiR. "In
DiamiR's ongoing biomarker programs, our main objective is to
provide researchers and clinicians with minimally invasive,
accurate molecular solutions for better characterization of
patients and monitoring disease severity and progression as well as
response to treatment during drug development."
About DiamiR
DiamiR is a privately held molecular diagnostics
company focused on developing minimally invasive tests for
detection and monitoring of pathology based on quantitative
analysis of organ-enriched microRNA signatures in plasma for
screening, patient stratification, as well as disease progression
and treatment monitoring. DiamiR collaborates with leading academic
centers, disease foundations, and biopharma companies. For more
information, please visit the company's website at
www.diamirbio.com.
This news release contains forward-looking
statements regarding future events. These statements are
predictions and are subject to risks and uncertainties that could
cause the actual events or results to differ materially.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Contact: Alidad
Mireskandari, PhD203-570-8275amireskandari@diamirbio.com